Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript Summary
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript Summary
The net loss narrowed to $1.4 million in Q3 2024 from $1.8 million in Q3 2023, while operating expenses were cut down to $1.5 million from $1.9 million.The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript:
以下是Tivic Health Systems, Inc. (TIVC) 2024年第三季度業績會交流摘要:
Financial Performance:
財務表現：
In Q3 2024, Tivic Health Systems reported revenues of $600,000, a 27% decrease compared to $819,000 in the same quarter of the previous year, attributed to a 36% decrease in unit sales offset by a 13% increase in average sales price per unit.
Gross profit decreased to $44,000 in Q3 2024 from $108,000 in Q3 2023, with gross margin slipping to 35% from 38% year-over-year mainly due to significant costs in supply chain redesign.
The net loss narrowed to $1.4 million in Q3 2024 from $1.8 million in Q3 2023, while operating expenses were cut down to $1.5 million from $1.9 million.
Cash reserves decreased to $2.2 million at the end of September 30, 2024 from $3.4 million at the end of December 31, 2023.
2024年第三季度，Tivic Health Systems報告收入爲60萬美元，比去年同期的81.9萬美元下降27％，主要歸因於銷量下降36％和單位銷售價格上漲13％相抵。
2024年第三季度，毛利潤從2013年第三季度的108,000美元下降至44,000美元，毛利率由38％下滑至35％，主要是由於供應鏈重設計所產生的重大成本。
淨虧損從2013年第三季度的180萬美元減少至2024年第三季度的140萬美元，而營業費用從190萬美元降至150萬美元。
截至2024年9月30日，現金儲備從2013年12月31日的340萬美元減少至220萬美元。
Business Progress:
業務進展：
Tivic Health has focused on turning the ClearUP product into a profitable line, leveraging their bioelectronic medicine expertise to explore new business opportunities, and enhancing efficiency in corporate operations.
Introduced ClearUP 2.0 after resolving technical issues and engaged strategic partners such as McKesson and Cardinal Health to scale distribution.
Advanced studies in non-invasive vagus nerve stimulation (VNS), having completed a trial showcasing strong data which shows promise for addressing various neurologic, cardiac and psychiatric conditions.
Tivic Health已專注於將ClearUP產品打造成盈利產品線，利用其生物電醫學專長探索新的業務機會，並提升公司運營效率。
解決技術問題後推出ClearUP 2.0，並與麥克森和卡地納健康等戰略合作伙伴合作，以擴大分銷規模。
進行了非侵入式迷走神經刺激（VNS）的先進研究，已完成一項展示強大數據的試驗，顯示了在處理各種神經學、心臟和精神疾病方面的前景。
Opportunities:
機會：
Expansion in the non-invasive vagus nerve stimulation market, which is projected to grow significantly, offering a new frontier for Tivic Health's innovative solutions.
Leveraging partnerships with significant distributors like McKesson and Cardinal to enhance the distribution reach and overall market penetration.
擴展非侵入式迷走神經刺激市場，預計將大幅增長，爲Tivic Health的創新解決方案開闢新的前沿。
利用與麥克森和卡地納等重要分銷商的夥伴關係，以增強分銷覆蓋範圍和整體市場滲透。
Risks:
風險：
The decline in sales for the ClearUP product line and the significant redesign and operational costs associated may pressure short-term financial stability.
Reallocating resources from improving ClearUP to developing the VNS program could risk the existing product's market position if not managed carefully.
ClearUP產品線銷售下降以及與重大重新設計和運營成本相關的壓力可能會影響短期財務穩定性。
將資源從優化ClearUP轉向開發VNS計劃，如果不小心管理，可能會冒險影響現有產品在市場上的地位。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
